Raludotatug deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with CDH6 expressing platinum-resistant...

FDA grants Fast Track Designation to Corbus Pharmaceuticals Nectin-4 targeting ADC CRB-701 in head and...

Hengrui Medicine has received its marketing authorization application for a new indication for its Ruikang...

Adagene expands SAFEbody collaboration and license agreement with Exelixis to develop third novel masked antibody-drug...

Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product...

Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody